Pharmaceutical Regulation and Intellectual Property: the Third Side of the Triangle

François Lévêque ()
Additional contact information
François Lévêque: CERNA i3 - Centre d'économie industrielle i3 - Mines Paris - PSL (École nationale supérieure des mines de Paris) - PSL - Université Paris Sciences et Lettres - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: This paper seeks to determine the interactions between industry-specific regulation law and patent law in the case of the pharmaceutical industry. It thus attempts to close the third side of the triangle formed by the vertices of antitrust, regulation and intellectual property. For a lack of academic references on the subject , this paper is obviously highly exploratory, raising more questions than it answers. The first section of the chapter contains an overview of the intersection between the three areas of law and a discussion of the differences and similarities between regulation and intellectual property law. The second section studies the previously neglected side of the triangle in the case of the pharmaceutical industry. The third section concludes with considerations on the application of antitrust law in the regulated, R&D-intensive pharmaceuticals industry.

Date: 2009
Note: View the original document on HAL open archive server: https://minesparis-psl.hal.science/hal-00488206v1
References: Add references at CitEc
Citations:

Published in 2009

Downloads: (external link)
https://minesparis-psl.hal.science/hal-00488206v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-00488206

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().